Stock Events

Stock Events

Tenaya Therapeutics 

$0.8305
121
-$0.01-1.51% 19:36 Today

Statistics

Day High
0.8305
Day Low
0.7758
52W High
2.35
52W Low
0.532
Volume
187,280,015
Avg. Volume
-
Mkt Cap
180.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.37
-0.27
-0.17
-0.06
Expected EPS
-0.064286
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-90.6MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNYA. It's not an investment recommendation.
NVIDIA
21
NVDA
Amazon
14
AMZN
Microsoft
12
MSFT
AMD
12
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the gene therapy space where Tenaya operates.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same innovative treatment space as Tenaya.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is a leading gene editing company using CRISPR/Cas9, competing in the broader gene therapy market.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine works on gene editing technologies, directly competing with Tenaya's gene therapy approaches.
Beam Therapeutics
BEAM
Mkt Cap3.36B
Beam Therapeutics focuses on precision genetic medicines using base editing, a form of gene editing competing with Tenaya's technologies.
Voyager Therapeutics
VYGR
Mkt Cap207.85M
Voyager Therapeutics specializes in gene therapy targeting the central nervous system, indicating competition in the gene therapy field.
Protagonist Therapeutics
PTGX
Mkt Cap8.45B
Protagonist Therapeutics is engaged in developing peptide-based therapies, a different approach but still in the realm of innovative treatments for diseases, including heart disease.

About

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Faraz Ali M.B.A.
Employees
70
Country
United States
ISIN
US87990A1060

Listings

XNAS
US
TNYA
BOATS
BOATS
TNYA.BOATS

0 Comments

Share your thoughts

FAQ

What is Tenaya Therapeutics stock price today?▼
The current price of TNYA is $0.83 USD — it has decreased by -1.51% in the past 24 hours. Watch Tenaya Therapeutics stock price performance more closely on the chart.
What is Tenaya Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tenaya Therapeutics stocks are traded under the ticker TNYA.
Is Tenaya Therapeutics stock price growing?▼
TNYA stock has fallen by -3.78% compared to the previous week, the month change is a +20.28% rise, over the last year Tenaya Therapeutics has showed a +13.44% increase.
What is Tenaya Therapeutics market cap?▼
Today Tenaya Therapeutics has the market capitalization of 180.22M
When is the next Tenaya Therapeutics earnings date?▼
Tenaya Therapeutics is going to release the next earnings report on August 12, 2026.
What were Tenaya Therapeutics earnings last quarter?▼
TNYA earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.09 USD resulting in a -2.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tenaya Therapeutics revenue for the last year?▼
Tenaya Therapeutics revenue for the last year amounts to 0 USD.
What is Tenaya Therapeutics net income for the last year?▼
TNYA net income for the last year is -90.6M USD.
How many employees does Tenaya Therapeutics have?▼
As of July 16, 2026, the company has 70 employees.
In which sector is Tenaya Therapeutics located?▼
Tenaya Therapeutics operates in the Health & Wellness sector.
When did Tenaya Therapeutics complete a stock split?▼
Tenaya Therapeutics has not had any recent stock splits.
Where is Tenaya Therapeutics headquartered?▼
Tenaya Therapeutics is headquartered in South San Francisco, United States.